Search

Displaying results 721 - 730 of 10000 in total
  1. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022. … Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults.

  2. Drug

    Tauroursodeoxycholic acid

    go.drugbank.com/drugs/DB08834
    ApprovedInvestigationalWithdrawn

    [A249080] Tauroursodeoxycholic acid is currently used in Europe to treat and prevent gallstones as a bile acid derivative. … Tauroursodeoxycholic acid, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid [A249070] that is produced in humans at a low concentration.

  3. Drug

    Topiramate

    go.drugbank.com/drugs/DB00273
    ApprovedInvestigational

    [A175249] It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults. … [A188309,L10544,L43478] Since 2012, the extended-release formulation has been approved in combination with [phentermine] for chronic weight management therapy in adults.

    Products: TOPIRAMATO EG, Topamax 15 mg Granulat in Kapseln
  4. Drug

    Diroximel fumarate

    go.drugbank.com/drugs/DB14783
    ApprovedInvestigational

    [A176474] It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. … Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019[L9626] and by the EMA in November 2021.[L39225]

  5. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and … safer for use in patients with contraindications to standard therapy.

  6. Drug

    Tezepelumab

    go.drugbank.com/drugs/DB15090
    ApprovedInvestigational

    [L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712] … It was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen/AstraZeneca.

  7. Drug

    Xanomeline

    go.drugbank.com/drugs/DB15357
    ApprovedInvestigational

    [L51713] It is approved as part of a combination product alongside [trospium], a muscarinic antagonist that acts primarily on peripheral muscarinic receptors in order to mitigate the risk and severity … [A264509] Advances in pre-clinical research and findings in clinical trials have led to a resurgence of interest in the cognition-enhancing potential of muscarinic agonists in schizophrenia, as it was

  8. Drug

    Secnidazole

    go.drugbank.com/drugs/DB12834
    ApprovedInvestigational

    [A245503] Secnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades. … [A245503, A245508] In September 2017, FDA approved secnidazole under the market name Solosec for the treatment of trichomoniasis and bacterial vaginosis.[L39524]

  9. Drug

    Ambroxol

    go.drugbank.com/drugs/DB06742
    ApprovedInvestigational

    Surfactants acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents. … role in the body’s natural defence mechanisms.

    Synonyms: Cyclohexanol, 4-((2-amino-3,5-dibromobenzyl)amino)- (E)-, N-(2-Amino-3,4-dibromociclohexil)-trans-4-aminociclohexanolMixtures: LARITOL EX, TUKOL EX
  10. Drug

    Bifenthrin

    go.drugbank.com/drugs/DB15056
    Experimental

    Bifenthrin is under investigation in clinical trial NCT01560247 (Percutaneous Recanalization in Ischemic Stroke Management in Europe Observational Registry).